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Endothelial Cell Mediators of Angiogenesis in Bartonella henselae Infection 
Amy M. McCord 
ABSTRACT 
 
Bacillary angiomatosis (BA), one of the clinical manifestations resulting from 
infection with the facultative intracellular bacterium Bartonella henselae, is characterized 
by angiogenic lesions.  Endothelial cells have been identified as host cells for this 
pathogen and are presumed important for pathogenesis as lesions contain bacteria in 
direct contact with the endothelium.  Lesions also contain infiltrating macrophages, 
which contribute to the angiogenic process during B. henselae infection by secreting 
vascular endothelial growth factor (VEGF).  While virulence factors have been 
characterized, and the role for macrophages in B. henselae infection has been established, 
endothelial cell mediators of angiogenesis have not been well defined.  We investigated 
three potentially important pathways that are triggered by the bacterial interactions with 
endothelial cells.  We examined the ability of endothelial cells to upregulate the 
chemokines monocyte-macrophage chemoattractant protein-1 (MCP-1) and CXCL8 and 
the mechanism by which B. henselae secreted proteins (BHSP) induce endothelial cell 
proliferation.  We determined that MCP-1 production is upregulated in response to B. 
henselae infection, which very likely contributes to angiogenic lesion formation by 
recruiting the VEGF-secreting macrophage.  The chemokine CXCL8 is an important 
mediator of angiogenesis which can cause endothelial cell survival, proliferation, and 
 viii
capillary tube formation.  We determined that CXCL8 is secreted from B. henselae-
infected cells and contributes to B. henselae-induced angiogenesis in an autocrine 
manner.  We also investigated the role of Ca2+ signaling during B. henselae infection.  
We determined that BHSP induce a robust intracellular Ca2+ response in HUVEC which 
originates from intracellular Ca2+ pools.  Additionally, endothelial cell proliferation in 
response to BHSP required Ca2+ activity, indicating a role for intracellular Ca2+ pools 
during B. henselae-induced angiogenesis.  Endothelial cell proliferation during B. 
henselae infection possibly indicates a mechanism by which a pathogen induces 
proliferation of its host cell in order to propagate its own survival.  Numerous factors 
culminate in the vascular lesions that are characteristic of BA.  B. henselae infection 
represents an important and unique model for pathogen-triggered angiogenesis, and 
studies into the specific mechanisms of this process may elucidate host cell-pathogen 
interactions as well as pathways of pathogenic angiogenesis. 
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Introduction 
 
Bartonella Species and Human Disease 
 Bartonellae are short, pleomorphic, gram negative rods which are fastidious, 
aerobic, oxidase negative organisms (4).  They are classified within the α2 subgroup of 
the class proteobacteria.  The single genus Bartonella was created by merging B. 
bacilliformis and the genus Rochalimaea (13).  There are currently 16 Bartonella spp. 
identified.  Figure 1 shows a parsimony tree for Bartonella species derived from 16s 
rRNA sequences (37).  Bartonella spp. cause a chronic intraerythrocytic bacteremia in 
reservoir hosts and are transmitted by arthropod vectors during feeding.  Bartonella can 
cause an asymptomatic bacteremia.  B. quintana, B. bacilliformis, B. elizabethae, B. 
grahamii, B. vinsonii subsp. berkhoffii, B. vinsonii subsp. arupensis, B. henselae, and B. 
clarridgeiae cause human disease.  B. qunitana causes trench fever, a recurrent fever 
transmitted by human body lice, bacteremia, and bacillary angiomatosis (BA).  B. 
bacilliformis causes Carrion’s disease and Orroya fever with chronic verrugae.   B. 
henselae causes cat scratch disease (CSD) and BA.  B. quintana, B. henselae, B. 
elizabethae, B. vinsonii subsp. berkhoffii, and B. vinsonii subsp. arupensis have been 
associated with endocarditis, usually in patients previously diagnosed with valvulopathy 
(31).
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Figure 1.   Comparison of parsimony tree (left side) and neighbor-joining tree 
(right side) derived from complete ITS sequences for recognized Bartonella 
species (type strains). The support of each branch, as determined from 
100 bootstrap samples, is indicated by the value at the node. The lengths of vertical 
lines are not significant. For the parsimony tree, the lengths of horizontal lines are 
also not significant. For the neighbor-joining tree, the scale bar represents 
evolutionary distance as calculated by using the Kimura two-parameter distance 
calculation. (37). 
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Bartonella henselae 
B. henselae are gram-negative bacilli that display twitching motility.  The genome 
size is around 1.9 X 106 bp (3).  There are two phases of B. henselae in culture: the rough 
and smooth forms.  The “rough” bacteria express a pilus-like structure that has been 
recently characterized as Bartonella adhesion A (BadA, see Virulence factors).  The 
presence of pili correlates with more efficient attachment to host cells (4).  The “rough” 
forms autoagglutinate, pit chocolate agar, and display a dry colony morphology (9).  In 
contrast, the phase variation to “smooth” B. henselae, which correlates with increased 
passage number, is characterized by mucoid, non-pitting colonies, no auto-agglutination, 
and fewer pili (9).   
 
Diseases Caused by Bartonella henselae 
 B. henselae is a flea-borne pathogen of cats and humans.  Blood donors in the 
USA and Australia exhibit a 3-6% seroprevalence for B. henselae (12, 19, 29, 39, 47).  
Two manifestations of B. henselae infection include CSD and BA.  CSD is a usually self-
limiting lymphadenitis.  While the lymph nodes usually regress after a period of weeks or 
months, in 10% of patients the lymphadenitis may become suppurative.  Additionally, 
rash, hepatosplenomegaly, lytic bone lesions, and deep lymphadenitis may also occur.  
The vasoproliferative diseases BA and bacillary peliosis (BP) occur preferentially in 
immunocompromised patients.  BA may occur with either B. henselae or B. quintana 
infections; however, BP is associated only with B. henselae (48).  BA  is a proliferative 
disorder of the vascular endothelium resulting in the formation of tumorous lesions on the 
skin (BA) and internal organs (BP) (86).   
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B. henselae Pathogenesis 
Bartonella spp.are unique among bacteria for causing angioproliferation.  
Endothelial cells appear to be important during BA and BP as the lesions contain bacteria 
in direct contact with the endothelium.  Histological examination of BA lesions has also 
revealed infiltration by polymorphonuclear leukocytes and macrophages.  B. henselae 
pathogenesis can be divided into the effects of pro-inflammatory activation in the 
endothelial cell, autocrine promotion of proliferation in endothelial cells, inhibition of 
endothelial cell apoptosis, stimulation of endothelial cell proliferation, and paracrine 
effects from infection of macrophages and epithelial cells. 
 
B. henselae-Induced Pro-Inflammatory Activation 
NFκB is a target for pathogens that either promote or inhibit inflammation.  NFκB 
activation in endothelial cells is characterized by surface expression of adhesion 
molecules such as E-selectin and intracellular adhesion molecule-1 (ICAM-1) and the 
release of Interleukin-8 (CXCL8, CXCL8).  During B. henselae infection of endothelial 
cells, endothelial cell adhesion molecules are upregulated and NFκB is activated (32).  
ICAM-1 expression is also upregulated on HUVEC in response to infection (60).  While 
many pathogens induce inflammation, only Bartonella spp. possess the ability to cause 
vasoproliferation.  The role of the inflammatory response in B. henselae pathogenesis is 
not well understood; however, the bacteria may utilize this mechanism to attract key 
regulators of angiogenesis such as macrophages to the sites of infection, which secrete 
pro-angiogenic molecules and growth factors. 
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B. henselae-Induced Endothelial Cell Survival and Proliferation 
Proliferation of endothelial cells is an important step during angiogenesis.  B. 
henselae causes proliferation and migration of endothelial cells in vitro (20).  B. henselae 
also causes enhanced survival of endothelial cells through inhibition of apoptosis.  This 
mechanism consists of an inhibition of caspases 3 and 8 (43).  Some aspects of B.  
henselae-induced endothelial cell proliferation are controversial and poorly defined.  For 
example, some argue that direct contact with the bacterium is needed for proliferation, 
since the angiogenic factor of B. henselae was localized to the particulate fraction of the 
bacterium (20).  Other studies revealed that direct contact is not needed for stimulation of 
endothelial cell proliferation, as the endothelial cells will proliferate if they are separated 
from the bacteria by a membrane (59).  Another hypothesis is that the paracrine effect of 
macrophages is needed for proliferation.  When supernatants from B. henselae-infected 
macrophages are added to endothelial cells, the cells proliferate at a higher rate than cells 
incubated with uninfected macrophage supernatants (71).  These data revealed a role for 
the macrophage during infection as the macrophage produced potent endothelial growth 
factors in response to B. henselae infection.  The effect of inhibition of apoptosis versus 
actual cell proliferation has also been debated (43, 77).  These differences may be due to 
different passages of bacteria used, differing multiplicities of infection (MOIs), and 
different phases of the bacteria.  Despite the presence of many conflicting ideas,     B. 
henselae causes angiogenesis through the culmination of a multitude of factors.   
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Paracrine Effectors During B. henselae–Induced Angiogenesis 
Peripheral cells are also key regulators of angiogenesis.  During B. henselae 
infection, polymorphonuclear lymphocytes and macrophages are present in the 
angiogenic lesions from BA (49, 50, 64).  Epithelial cells as well as macrophages 
produce VEGF in response to infection with B. henselae (41, 71, 77), which most likely 
also contributes to vascular proliferation during B. henselae infection.  CXCL8 is also 
produced by B. henselae-infected epithelial cells (71, 77).  These paracrine factors may 
also play a vital role in B. henselae induced endothelial cell proliferation and 
angiogenesis.  A model of autocrine and paracrine effects on endothelial cells during B. 
henselae  infection, which shows the relative contributions of peripheral and host cells in 
B. henselae-induced angiogenesis, is depicted in Figure 2 (71).  
 
B. henselae Virulence Factors 
The recent sequencing of the B. henselae genome has opened many new 
investigations into B. henselae virulence factors.  While earlier investigations identified 
some putative virulence factors, such as outer membrane proteins (OMPs) and secreted 
factors, further identification and mutagenesis of new and important virulence factors has 
been facilitated recently.  Recently identified or characterized virulence factors include 
the Type IV secretion system (TFSS), lipopolysaccharide (LPS), GROEL, and BadA. 
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Figure 2.  Model of paracrine and autocrine mechanisms of B. henselae-
mediated angiogenesis.  B. henselae is able to adhere to and invade human 
macrophages (mac) and induce production of VEGF. This secreted VEGF 
functions in a paracrine manner and acts as an endothelial cell mitogens when it 
binds to its receptors on endothelial cells. Infection of endothelial cells (EC) with 
B. henselae may serve to further enhance proliferation by NFκB activation through 
upregulation of adhesion molecules such as E-selectin and ICAM-1.  Also, 
chemokines may be produced upon endothelial cell infection which would attract 
macrophages leading to enhanced growth factor signaling.  In addition, caspases 
are inhibited in infected endothelial cells leading to enhanced endothelial cell 
survival (Resto-Ruiz et.al., 2002).   
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TFSS 
 TFSS are multicomponent transport systems of gram-negative bacteria.  They can 
mediate transfer of diverse factors, from effector proteins to DNA.  The B. henselae 
TFSS is encoded by the virB operon.  The virB operon is induced during endothelial cell 
infection (79).  It has been recently determined that the TFSS encoded by the virB operon 
mediates invasion, proinflammatory activation, and anti-apoptotic protection of 
endothelial cells (77).  However, at higher MOIs (larger than 50) the TFSS has a 
cytotoxic effect on the endothelial cell.  Thus the proteins coded by virB are important for 
endothelial cell survival and invasion.  This does not necessarily exclude the possibility 
of a factor which mediates proliferation.  Recently a model of the TFSS apparatus was 
suggested which includes interactions between the VirB2 pilus-associated protein and 
VirB3 and VirB5 (Fig. 3) (81).   
 Recently, the proteins which are translocated by the TFSS machinery were 
identified as Bartonella effector proteins (Beps) A-G (80).  Also, the VirD4 TFSS 
coupling protein was identified.  BepD is translocated into HUVECs in a VirB/VirD4 
dependent manner.  The endothelial cell response to B. henselae with a deletion of the 
virB4 includes a decrease in NFκB activation, endothelial cell survival, and bacterial 
invasion (77).  B. henselae with deletions of bepA-G or virD4 induced an endothelial 
response similar to that elicited from the endothelial cells infected with the virB4 deletion 
mutant (80). 
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Figure 3.  Structure of TFSS apparatus of B. henselae.  The proteins coded by the 
virB operon of B. henselae are thought to assemble as depicted here.  VirB2 is 
thought to be the main conduit through which proteins are transported, which is 
driven by the VirB11 ATPase.  VirB4 binds to itself as well as VirB10.  VirB10 
interacts with both VirB8 and VirB9.  VirB5 and VirB3 exhibit the strongest 
interaction (Shamaei-Tousi et. al., 2004). 
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Outer membrane proteins (OMPs)  
The outer membrane of gram-negative bacteria serves as an interface between the 
host cell and the pathogen.  B. henselae expresses a variety of outer membrane  
components, including lipopolysaccharide and a hemin-binding protein (HbpA), 
immunoreactive antigens, and a red blood cell invasion protein (IalB) (17).  OMPs of 43-
kDa and 66-kDa molecular masses bound HUVEC membrane components (14).  B. 
henselae OMPs are important for pathogenesis (14, 32) and they have been implicated in 
an NFκB-dependent proinflammatory activation of endothelial cells (32).  OMPs activate 
HUVEC dose-dependently as measured by E-selectin and ICAM-1 protein expression 
(32).  They also bind HUVEC membrane proteins and may be important for bacterial 
adhesion and entry (14). 
 
Bartonella Adhesin A (BadA) 
Until recently, a putative Type IV pilus on the surface of B. henselae was 
presumed to exist (9).  Transmission electron microscopy of B. henselae strains showed 
the presence of a pilus-like structure on the surface of the bacterium (9).  This “pilus” 
mediates VEGF secretion from macrophages and host cell adhesion (41).  The presence 
of the pili correlates with the “rough” phenotype of B. henselae.  Recently, when the B. 
henselae genome was published (3) it was clear that the gene for the putative Type IV 
pilus was not present.  Subsequently, the projections were determined to be homologous 
to the non-fimbrial adhesin Yersinia adhesion A (YadA) and were renamed BadA 
accordingly (72).  Non-fimbrial adhesins are non-pillin structures which contain a 
connector domain, a fibrous stalk, and a C-terminus anchoring domain (69).  BadA 
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mediates interaction of B. henselae with extracellular matrix proteins (ECM).  In 
addition, BadA activates an important mediator of angiogenesis, hypoxia inducible factor 
(HIF-1), and elicits an anti-BadA immune response in mice and rabbits (72).  Thus BadA 
is important for B. henselae infection and also may serve as a clinical marker for 
infection (72).   
 
Lipopolysaccharide (LPS)  
Although LPS is usually considered a pathogenic factor in Gram-negative 
bacteria, the LPS from B. henselae exhibits remarkably low endotoxicity.  Bacteremic 
patients display no signs of septic shock.  Unique components of the LPS structure 
include a pentaacyl Lipid A and a small inner core composed of an α-(2→4)-linked Kdo 
disaccharide with one glucose residue attached (97).  In addition, B. henselae LPS does 
not signal through TLR4 or TLR2 (97).  This low endotoxicity is consistent with other 
intracellular bacteria such as Legionella and Chlamydia spp. 
 
GroEL 
 The heat shock response of B. henselae begins at temperatures of 37°C, human 
body temperature.  The heat shock response includes production of GroEL, a 60 kDa 
protein; GroES, a 10 kDa protein; and DnaK, a 70 kDa chaperonin (35).  GroEL from B. 
bacilliformis is mitogenic for HUVEC (63). B. henselae GroEL, although less potent, is 
also mitogenic for HUVEC (63).  Antibodies to GroEL inhibit proliferation of HUVEC in 
response to B. bacilliformis lysate.  GroEL was also present as a secreted protein (63). 
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Angiogenesis 
 
Overview 
Pathogenic (tumor or inflammatory) angiogenesis provides a survival mechanism 
for the tissues of tumors and tumor-like lesions (30).  Angiogenesis is a multistep process 
during which the vessel wall disassembles, the basement membrane is degraded by 
matrix metalloproteinases (MMPs), endothelial cells migrate and invade the extracellular 
matrix, endothelial cells proliferate, and a capillary lumen is formed.  Angiogenesis 
requires cooperation between cells, cytokines, growth factors, and matrix components.  A  
sensitive balance between angiostatic and angiogenic factors must exist in order to 
control angiogenic activity; however in tumors and tumor-like lesions, this tightly 
regulated system is upset (36).  Angiogenesis is associated with conditions that involve 
inflammatory cell infiltrate (34), such as cancer, papopavirus infection, and herpesvirus 
infection (7, 15, 28, 55, 61).  Angiogenesis and inflammation coordinate through 
common stimuli for endothelial cells and leukocytes; these stimuli include chemokines.  
Angiogenic chemokines exert a direct effect on the endothelium and an indirect effect on 
angiogenic-factor expressing leukocytes (68, 88).  Chemokines are induced by TNF or 
IL-1 or by interaction with bacterial pathogens and recruit leukocytes to sites of 
inflammation.   
 
 
 
 13
Chemokines – MCP-1 
Monocyte-macrophage chemoattractant protein-1 (MCP-1) is a potent and 
specific monocyte agonist and chemoattractant (33, 96) which is produced by endothelial 
cells, smooth muscle cells, and macrophages in response to various stimuli, including 
LPS (93).  MCP-1 stimulates chemotaxis of monocytes and macrophages to sites of 
inflammation (51).  MCP-1 can also directly promote angiogenesis (68, 88).  Thus MCP-
1 could play dual roles in B. henselae-induced angiogenesis by acting in an autocrine 
manner on endothelial cells to promote angiogenesis, while recruiting macrophages, the 
effector cell in the model, to the site of infection. 
 
Chemokines – CXCL8 
CXCL8 is a member of a family of 8 structurally related chemokines that have 
been shown to induce angiogenesis.  CXCL8 augments angiogenesis through enhanced 
endothelial cell survival, proliferation, and MMP production  (52, 53).  CXCL8 receptors 
CXCR1 and CXCR2 are widely expressed on normal and tumor cells (38, 84, 85, 95) and 
have been observed on endothelial cells (67, 74).  These receptors also play a role in 
proliferation of endothelial cells (46).   
 
Ca2+ Signaling 
 Calcium homeostasis may regulate important cellular functions including 
activation of signal transduction pathways, proliferation, invasion, and differentiation 
(26, 65, 75, 87).  Ca2+ plays a key role during angiogenesis; however, the mechanisms 
involved are not fully explained (2).  Depletion of intracellular pools of Ca2+ and not 
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cytosolic Ca2+ levels inhibits proliferation and migration of human vascular smooth 
muscle cells (10, 83).  In addition, inhibition of intracellular Ca2+ pools with thapsigargin 
inhibits angiogenesis in the rat isolated aorta (82).  Intracellular Ca2+ pools are crucial 
mediators of angiogenesis. 
 
B. henselae and Angiogenesis 
B. henselae-induced angiogenesis is reminiscent of tumor angiogenesis.  B. 
henselae-induced angiogenesis represents a paradigm for pathogen-triggered tumor 
formation (22).  Recently, the steps for B. henselae-induced angiogenesis have been 
clarified to most likely include (i) an NFκB-dependent proinflammatory activation, (ii) 
inhibition of endothelial cell apoptosis, (iii) direct endothelial cell proliferation, and (iv) 
growth factors produced from peripheral cells.   
 During angiogenesis, endothelial cells migrate and proliferate, then organize into 
vessels.  As well as promoting endothelial cell proliferation, B. henselae causes 
angiogenesis in vitro.  Kirby et. al. demonstrated that B. henselae promotes survival of 
endothelial cords and promotes invasion, survival, and differentiation in a collagen 
matrix (42).  Thus in addition to inhibition of apoptosis and endothelial cell proliferation, 
B. henselae promotes capillary tube formation.  Unfortunately, no small animal model of 
B. henselae-induced angiogenesis has been successfully developed.  Zhang et. al. 
developed an animal model for B. quintana infection utilizing rhesus macaques (Macaca 
mulatto) (98).  This model mimics the high-titer bacteremia in humans. A small animal 
model would allow for functional in vivo studies with bacterial mutants, further defining 
the roles of virulence factors in an in vivo environment. 
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B. henselae-induced angiogenesis represents a unique phenomenon in which a 
bacterium induces angiogenic lesions.  One possible rationale for pathogen-induced 
angiogenesis during Bartonella infections is that the pathogen may improve its survival 
by propagation of its host cell.  Vascularization during infection is exclusive for 
Bartonella spp.  While many bacterial virulence factors have been characterized, the 
effects of these factors on the host cell are unknown.  There are most likely numerous 
factors culminating in the vascular lesions that are a characteristic of BA.  However, 
specific investigations into the direct effect of the bacterium on human endothelial cells 
may clarify pathogenic mechanisms of angiogenesis.   
 16
 
 
 
 
 
Objectives 
 
B. henselae causes angiogenic lesions in the immunocompromised, a 
phenomenon unique to Bartonella spp.  These lesions contain bacteria in direct contact 
with the endothelium as well as infiltrating macrophages and polymorphonuclear 
leukocytes.  Macrophages secrete VEGF in response to B. henselae infection, thus they 
are thought to be quite important during infection.  However, the bacteria induce 
endothelial cell proliferation in the absence of macrophages as well, so while VEGF 
signaling is probably important in vivo, there may also be direct stimulation of 
proliferation by the bacterium.  Since the bacterial genome was published recently, there 
has been much progress in identification and characterization of virulence factors.  
However, the endothelial mechanisms contributing to angiogenesis during B. henselae 
infection have not been fully clarified.  This study was developed to identify important 
endothelial cell mediators of angiogenesis during B. henselae infection and to identify the 
mechanisms involved in the upregulation of these factors.  Investigations into endothelial 
cell contributions during B. henselae–induced angiogenesis may reveal the factor or 
factors responsible for angioproliferation.  A review of the current literature led to the 
following hypothesis:  
 
B. henselae causes upregulation of pro-angiogenic factors during infection of 
endothelial cells, which contributes to the overall pathogenesis of B. henselae. 
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In order to refute or support this hypothesis, the following objectives were formulated: 
 
1.  To determine if B. henselae upregulates macrophage chemoattractant protein-1 
production and expression in endothelial cells and the mechanism by which this occurs. 
 
2.  To determine the role of CXCL8 in B. henselae-induced endothelial cell proliferation, 
survival, and capillary tube formation.  
 
 
3.  To determine the effect of B. henselae secreted proteins on endothelial cell 
proliferation. 
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Materials and Methods 
 
Bacterial Strains.   
Bartonella henselae Houston-1 (ATCC 49882) (70) strain was grown on 
chocolate agar prepared with heart infusion agar base (Difco, Detroit, MI) supplemented 
with 1% bovine hemoglobin (Beckton Dickinson, Cockeysville, MD).  Bacterial cultures 
were maintained at 37°C and 5% CO2 and humidity to saturation.  For certain 
experiments, bacteria were heat-killed at 100°C for 30 minutes as described previously 
(71).  Escherichia coli JM109 strain was grown in Luria-Bertani broth or agar (Difco). 
 
Cell Lines.   
The immortalized human microvascular cell line (HMEC-1) (1) was cultured in 
MCDB131 cell culture media (Gibco BRL, Grand Island, NY) supplemented with 10% 
fetal calf serum (FCS) (Hyclone Laboratories, Logan, UT), 10 ng/ml epidermal growth 
factor, 1.461 g/L L-glutamine, 1 µg/ml hydrocortisone, 50 µg/ml penicillin-streptomycin, 
2.5 µg/ml amphotericin B (Sigma-Aldrich, St. Louis, MO), 2 mg/ml sodium bicarbonate, 
and 10 mM HEPES (Mediatech, Herndon, VA).  Human THP-1 monocytes (90) were 
cultured in RPMI 1640 medium (Sigma-Aldrich) supplemented with 10 % FCS, 5 µM 2-
mercaptoethanol (Sigma-Aldrich), 10 µg/ml vancomycin (Sigma-Aldrich), and 1 µg/ml 
amphotericin B.    Human umbilical vein endothelial cells (HUVEC) were obtained from 
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Clonetics Corporation (San Diego, CA) and were cultured in EGM (Clonetics).  HepG2 
cells were obtained from American Type Culture Collection (Manassas, VA) and were 
cultured in MEM containing 10% fetal calf serum, 1.5 g/L sodium bicarbonate, 0.1 mM 
non-essential amino acids, and 1.0 µM sodium pyruvate.  Cells were maintained at 37°C 
and 5% CO2 and humidity to saturation.  HUVEC were used in experiments at passages 
from 4 to 7. 
 
HMEC-1 Infections.   
Prior to infection, the culture medium containing antibiotics was removed from 
cell cultures and replaced with media without antibiotics or growth factors.  Cells were 
permitted to adapt overnight.  B. henselae Houston-1 were harvested from chocolate agar 
and suspended in cell culture media, then concentration of bacteria was determined 
spectrophotometrically as described previously (44).  Briefly, at OD600, a reading of 0.5 
correlates with 109 colony forming units (cfu)/ml.  B. henselae were added to cells at the 
multiplicity of infection (MOI) indicated.  Cells were co-cultured with Houston-1 for 
various timepoints.   
For E. coli co-cultures, JM109 were harvested into cell culture medium and added 
to cells at a density of 100 E. coli cells per HMEC-1, also determined 
spectrophotometrically.  During the experiments with longer time courses and during 
inhibition assays, E. coli LPS (Sigma-Aldrich) was used as a positive control for MCP-1 
production in order to keep HMEC-1 alive as E. coli JM109 infection was found to be 
cytotoxic for HMEC-1 at later time points.   
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Infections for CXCL8 ELISA.   
To generate supernatants for the analysis of CXCL8 secretion, HUVEC, HepG2, 
HMEC-1, or THP-1were placed into 24-well tissue culture plates (Costar, Cambridge, 
Mass.) at 90% confluency.  THP-1 were differentiated by overnight incubation with 1 µM 
vitamin D3 (Sigma-Aldrich).  Nonadherent cells were removed by washing.  Cells were 
infected with the Houston-1 strain of B. henselae as described previously using the 
appropriate cell culture medium with no antibiotics (71).  For the downstream analyses 
real-time PCR and capillary tube formation, the infections and incubations post-infection 
were carried out under serum-free conditions.  Cells were infected at indicated MOIs.   
 
CXCL8 ELISA.  
To determine CXCL8 levels in supernatants from B. henselae-infected cells, the 
DuoSet ELISA development systems (R&D Systems, Minneapolis, Minn.) for human 
CXCL8 was used according to the manufacturer's directions. The 3,3',5,5'-
tetramethylbenzidine Liquid Substrate System (Sigma-Aldrich) was added and left for 20 
min. The horseradish peroxidase reaction was stopped with 2 N sulfuric acid. ELISA 
plates were analyzed using a µQuant plate reader (Bio-Tek, Winooski, VT.) at 450 nm.  
HUVEC proliferation assay.  HUVEC were seeded in 96-well plates at 1x103 cells per 
well in media without antibiotics and allowed to adapt overnight.  Cells were infected the 
following day with Houston-1 at an MOI of 50 or incubated with recombinant human 
CXCL8 (100 ng/ml, R&D Systems).  Anti-human CXCL8 (10 µg/ml) or an isotype 
control (mouse IgG1, 10 µg/ml) were added to cell media during infections.  After 72 
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hours, cells were fixed and examined with an inverted microscope and digital pictures 
were taken with a Kodak DC290.  Cells were examined for qualitative differences in 
number.  In addition, cells were counted in 5 high-powered fields per well and averaged.     
 
LPS and TLR Inhibition Assays.   
Polymyxin B sulfate (Sigma-Aldrich) was used to neutralize the bacterial LPS in 
some experiments.  Houston-1 or E. coli JM109 or purified E. coli LPS was incubated 
with 30 µg/ml polymyxin B sulfate for 1 hour at 37°C and 5% CO2 before adding to 
HMEC-1.  In some experiments, HMEC-1 were preincubated with a mouse monoclonal 
antibody (HTA 125) specific for toll-like receptor-4 (TLR-4) (e-Bioscience, San Diego, 
CA) in order to determine if TLR-4 signaling was required for MCP-1 production.  
HMEC-1 were pre-incubated with 20 µg/ml anti-TLR4 for one hour at 37°C with gentle 
shaking, then co-cultures proceeded as usual and supernatants were collected eight hours 
after addition of bacteria or LPS.  Live E. coli JM109 were cultured with HMEC-1 during 
some experiments in order to ensure that the TLR4 monoclonal antibody would block 
activity from the LPS of live E. coli as well as from purified LPS.  An isotype control 
(mouse IgG2a, κ) (e-Bioscience) was used as a control antibody at 20 µg/ml.  During 
NFκB inhibition assays, HMEC-1 were incubated with 50 µM 
pyrrolidinedithiocarbamate (PDTC) (Sigma) or 100 µM N-tosyl-L-phenylalanine (TPCK) 
(Sigma) for one hour at 37°C with 5% CO2 before infections.  Inhibitors were maintained 
throughout the course of the assays. 
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Semiquantitative RT-PCR –mcp1.   
RT-PCR was performed on HMEC-1 co-cultured with B. henselae or E. coli at 
the indicated times after infection.  Total RNA was extracted with Trizol reagent (Sigma-
Aldrich) according to manufacturer’s protocol. Total RNA was treated with RNase-fee 
DNase (Ambion, Inc., Austin, TX) according to the manufacturer’s instructions.  
Concentration of RNA was determined spectrophotometrically using a GeneQuant II 
(Pharmacia Biotech, Cambridge, England).  cDNA preparation and subsequent PCR 
amplification were carried out by a One-Step RT-PCR kit (Qiagen, Inc., Valencia, CA) in 
the presence of gene-specific primers and 2 µg total RNA.  The PCR conditions were 1 
min at 95°C, 1 min at 58°C, and I min at 72°C for 35 cycles.  Primer sequences for RT-
PCR were as follows: β-actin forward 5’-AGAAAATCTGGCACCACACC-3’; β-actin 
reverse: 5’-CCATCTCTTGCTCGAAGTCC-3’; MCP-1 forward 5’-
TTCTCAAACTGAAGCTCGCACTCTCGCC-3’;  MCP-1 reverse: 5’-
TGTGGAGTGAGTGTTCAAGTCTTGGGAGTT-3’.  PCR products were analyzed by 
electrophoresis through 2% agarose gels and were visualized by ethidium bromide 
staining.  Amplicon sizes were 434 bp and 348 bp for β-actin and MCP-1 primers, 
respectively.  RT-PCR data were analyzed by scanning densitometry of gel bands with 
Kodak 1D Image Analysis software and normalizing to β-actin signals obtained from the 
same time points.  RT-PCR reactions included a no template control and a no reverse 
transcriptase control to exclude DNA or RNA contamination. 
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RNA Extraction and Reverse Transcription.   
Cells were infected at an MOI of 100 with Houston-1 or incubated with 100 ng/ml 
rCXCL8.  10 µg/ml anti-CXCL8 or an isotype control was added at the time of infection.  
After 24 hours, total RNA was extracted from HUVEC using TRIzol® reagent (Sigma-
Aldrich) according to manufacturer’s protocol.  Turbo DNA-free (Ambion, Austin, TX) 
was used to remove remaining DNA according to manufacturer’s protocol.  Two 
micrograms of total RNA were transcribed with AMV reverse transcriptase (Promega, 
Madison, WI) and used for real-time PCR or semi-quantitative RT-PCR. 
 
Real-Time PCR.   
Primers used for real-time PCR were as follows: β-actin forward 
5′ACCAACTGGGACGACATGGAGAAA3′,   β-actin reverse 5′-TAGCACAGCCTGG 
ATAGCAACGTA-3′;  Bax forward 5′-TCTACTTTGCCAGCAAACTGGTGC-3′, Bax 
reverse 5′-TGTCCAGCCCATGATGGTTCTGAT-3′; Bcl-2 forward 5′-ATTTCCTGCA 
TCTCATGCCAAGGG-3′,  Bcl-2 reverse 5′-TGTGCTTTGCATTCTTGGACGAGG-3′.  
β-actin was used as the housekeeping gene control.  Real-time PCR was performed with a 
Bio-Rad iQ iCycler Detection System (Bio-Rad Laboratories, Ltd.) with iQSYBR Green 
supermix (Bio-Rad Laboratories, Inc., Hercules, CA).  Reactions were performed in a 
total volume of 25 µl with 400 nM concentrations of primers.  Reactions consisted of 10 
minutes at 95°C, 45 cycles of 15 s at 95°C, 15s at 58°C, and 30 s at 72°C.  Melt curve 
analysis was used to determine PCR specificity.  Melt curve analysis was run with 80 
cycles of 10 s at 55°C with each cycle raising 0.5°C.  All reactions were carried out in at 
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least duplicate for each sample.  The standard curve method was used to determine 
amounts of each transcript.  Relative expression of Bcl-2 or Bax was determined by 
dividing amount (ng) of Bax or Bcl-2 by amount of β-actin in each sample.  Relative 
induction was determined by normalizing the relative expression of the uninfected 
control samples to 1.  All experiments included no template controls and untranscribed 
(noRT) RNA controls.   
 
Semiquantitative RT-PCR – cxcr1,cxcr2.  
Reverse transcription-PCR (RT-PCR) was performed on HUVEC 24 hours after 
infection. Total RNA was extracted as described above.  cDNA preparation and 
subsequent PCR amplification were carried out with a One-Step RT-PCR kit (QIAGEN, 
Inc., Valencia, CA) in the presence of gene-specific primers and 2 µg total RNA. The 
PCR conditions were 1 min at 95°C, 1 min at 58°C, and 1 min at 72°C for 35 cycles. 
Primer sequences for RT-PCR were as follows: for ß-actin forward, 5'-AGAAAA 
TCTGGCACCACACC-3'; for ß-actin reverse, 5'-CCATCTCTTGCTCGAAGTCC-3'; for 
CXCR2 forward, 5'-ATTCTGGGCATCCTTCACAG-3'; and for CXCR2 reverse, 5'-
TGCACTTAGGCAGGAGGTCT-3'.  PCR products were analyzed by electrophoresis 
through 2% agarose gels and were visualized by ethidium bromide staining.  RT-PCR 
data were analyzed by scanning densitometry of gel bands with Kodak 1D Image 
Analysis software and normalizing to ß-actin signals obtained from the same time points. 
RT-PCRs included a no-template control and a no-reverse-transcriptase control to 
exclude DNA or RNA contamination.  
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MCP-1 ELISA.   
MCP-1 levels in infected and uninfected HMEC-1 supernatants were assayed by 
MCP-1 DuoSet ELISA development system (R & D Systems, Minneapolis, MN) 
according to manufacturer’s protocol.  The 3, 3’, 5, 5’- tetramethylbenzidine liquid 
substrate system (Sigma-Aldrich) was added and the color was allowed to develop for 20 
minutes.  The reaction was stopped with 2N sulfuric acid.  ELISA plates were analyzed 
using a µQuant platereader (Bio-Tek, Winooski, VT) at 450 nm.   
 
Isolation of B. henselae LPS.   
B. henselae LPS was isolated as described previously (92).  Briefly, 3-day-old 
bacteria were harvested from chocolate agar and suspended in PBS.  The bacterial pellet 
was washed three times with sterile water.  Bacteria were lysed with lysis buffer (6% 
SDS, 60 mM Tris, 46% glycerol, 6% β-mercaptoethanol, 10mM dithiothreitol) at 100°C.  
Proteins were digested with proteinase K treatment.  These crude extracts were 
concentrated by centricon YM-3 (Millipore Corp., Bedford, MA).  Crude LPS was 
dialyzed against sterile endotoxin-free water for four days.  
 
Enrichment of Outer Membrane Proteins from B. henselae and Fractionation by 
Molecular Weight.  
B. henselae outer membrane proteins (OMPs) were enriched after inner 
membranes of total membrane preparations were solubilized with sarkosyl (14, 27).  The 
sarkosyl-insoluble pellet was resuspended in 10 mM HEPES (pH 7.4).  Protein 
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concentrations were determined using the Lowry protein assay (56).  600 µg protein in 
400 µl Laemmli sample buffer with 142 mM 2-mercaptoethanol were heated at 95°C for 
5 minutes and separated in a single large well of a 2-dimensional 4-12% Bis-Tris 
NuPAGE gel (Invitrogen, Carlsbad, CA).  Four sections of the gel were excised 
corresponding to 3-33kDa (OMP-1), 34-52 kDa (OMP-2), 53-97 kDa (OMP-3), and 98+ 
kDa (OMP-4).  Each section was minced and proteins were eluted using the Model 422 
Electro-Eluter (Bio-Rad, Hercules, CA) running at 30 milliamps for three hours in elution 
buffer consisting of 25 mM Tris base, 192 mM glycine, and 0.1% SDS.  Buffer was then 
exchanged using Microcon-YM-3 filters (Millipore Corp).  Protein concentrations were 
determined using the Lowry protein assay (56).  During some experiments, the lower 
molecular weight fraction of OMPs (OMP-1) was treated with polymyxin B sulfate (30 
µg/ml) or proteinase K.  OMP-1 was added to proteinase K (10 µg/ml) and incubated at 
55°C for 3 hours.  Proteinase K was inactivated at 100°C for 15 minutes.   
 
HUVEC Proliferation Assay.   
HUVEC were seeded in 96-well plates at 1x103 cells per well in media without 
antibiotics and allowed to adapt overnight.  Cells were infected the following day with 
Houston-1 at an MOI of 50 or incubated with recombinant human CXCL8 (100 ng/ml, 
R&D Systems).  Anti-human CXCL8 (10 µg/ml) or an isotype control (mouse IgG1, 10 
µg/ml) were added to cell media during infections.  After 72 hours, cells were fixed and 
examined with an inverted microscope and digital pictures were taken with a Kodak 
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DC290.  Cells were examined for qualitative differences in number.  In addition, cells 
were counted in 5 high-powered fields per well and averaged.     
Chemotaxis of THP-1 Monocytes.   
Chemotaxis of THP-1 monocytes was examined with modified Boyden chambers 
(Neuroprobe, Cabin John, MD) according to manufacturer’s instructions.  Briefly, the 
lower well of the chamber was filled with 1.2ml supernatants from uninfected, B. 
henselae-infected, or E. coli-infected HMEC-1.  510 µl of THP-1 cell suspension (5 x 105 
cells) were added to the upper well.  A 5 µm pore size PVP-free polycarbonate membrane 
(Neuroprobe) separated the two wells.  Migration occurred while incubating the 
chambers at 37°C and 5% CO2 with humidity for four hours.  After four hours, the upper 
side of the membrane was scraped with a sterile swab soaked in PBS three times to 
remove non-migrated cells and the lower side of the membrane was fixed and stained 
with Hema-3 Stat Pack (Biochemical Sciences, Inc., Swedesbord, NJ) according to 
manufacturer’s instructions.  Cells were counted in five high-powered fields per 
membrane and these numbers were averaged.  Cell counts ranged from 6 to 10 cells per 
high-powered field, with the exception of cells migrated in response to uninfected 
HMEC-1 supernatants, in which case zero to two cells were counted per microscope field 
as a result of much less migration of THP-1 cells.  Results are expressed as a chemotactic 
index (CI), in which the average number of cells that migrated in response to uninfected 
HMEC-1 supernatants was set to one.  A graph of the means of CIs for three experiments 
is shown.   
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In vitro Capillary Tube Formation Assay.  
A 96-well plate was coated with growth factor-reduced (GFR) Matrigel (BD 
Biosciences, Mountain View, CA).  The matrigel contained no antibodies, a control 
isotype, or anti-CXCL8 (10µg/ml).  The matrigel was solidified at 37°C for one hour, 
after which 104 uninfected or B. henselae-infected (MOI=100) HUVEC were added to 
each well.  rCXCL8 (100 ng/ml) was added to some wells containing uninfected cells at 
this time.  After 18 hours, plates were examined for qualitative differences in capillary 
tube formation and photographs were taken with a Kodak DC290 digital camera.   
 
Generation of B. henselae Secreted Proteins (BHSP). 
 B. henselae were harvested from chocolate agar plates and suspended in RPMI 
1640.  B. henselae were allowed to continue growth in flasks in RPMI 1640 for 24 hours 
at 220 rpm on an orbital shaker.  After 24 hours of incubation, the suspension was 
removed from the flask and spun at 2000 rpm for 10 minutes to form a soft pellet.  The 
supernatant was removed and passed through a 0.22 µm filtered to remove all bacteria.  
The bacteria-free supernatant was then concentrated in a Centricon-Plus 20 per 
manufacturer’s instructions (Millipore, Billerica, MA).  Protein concentrations were 
determined by bicinchoninic acid assay (Pierce, Rockford, IL).   Proteins were run on a 4-
12% NuPAGE gel (Invitrogen) and visualized by silver staining (Bio-Rad).  A vehicle 
control was also generated with identical methods, except that bacteria-free agar plates 
were swabbed and resuspended in RPMI 1640. 
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Western Blotting. 
BHSP (10 µg) or vehicle control were run on NuPAGE gels and transferred to 
nitrocellulose membranes in the presence of NuPAGE transfer buffer (Invitrogen) 
according to manufacturer’s instructions.  Alternatively, 10 µg BHSP or vehicle control 
were dotted on a nitrocellulose membrane. The membranes were blocked with TBST-5% 
skim milk overnight.  The membranes were washed four times with TBST and then 
incubated with rabbit anti-BadA (1:1000 in blocking buffer) or rabbit anti-GROEL 
(1:500 in blocking buffer).  The membranes were washed four times with TBST and 
incubated with a goat anti-rabbit antibody conjugated to horseradish peroxidase (1:5000 
in blocking buffer).  The membranes were washed and bands or dots were detected using 
the ECL chemiluminescent substrate (Amersham Biosciences, Buckinghamshire, UK) 
and exposure to X-ray film. 
 
Proliferation Assays with BHSP.   
HUVEC were seeded in 96-well plates at a density of 103 cells per well and 
allowed to attach overnight in media without antibiotics.  BHSP or vehicle controls were 
added in EBM containing no antibiotics at indicated concentrations.  After 72 hours, the 
HUVEC were photographed and 5 high-powered fields per well were counted and 
averaged. 
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Measurement of CXCL8 Levels from BHSP-Treated HUVEC. 
 HUVEC were treated with various concentrations of BHSP or medium controls.  
After 24 hours, the cell culture supernatants were collected and an ELISA was used to 
measure the CXCL8 levels as described under “CXCL8 ELISA”.   
 
 
Ca2+ Imaging. 
The calcium-sensitive dye fura2/AM was used for measuring intracellular free 
calcium concentrations in HUVEC, as previously described. Cells plated on coverslips 
were incubated for 1 h at room temperature in physiological saline solution (PSS) 
consisting of 140 mM NaCl, 3 mM KCl, 2.5 mM CaCl2, 1.2 mM MgCl2, 7.7 mM glucose, and 
10 mM HEPES (pH to 7.2 with NaOH), which also contained 1 µM fura-2/AM and 0.1% 
Me2SO. The coverslips were then washed in PSS (fura-2/AM-free) prior to the 
experiments being carried out. PSS was applied via a rapid application system.  B. 
henselae secreted proteins (BHSP) were applied with a pipette to the coverslip.  
Concentrated liquid culture media containing no bacteria served as a vehicle control.   
A DG-4 high speed wavelength switcher (Sutter Instruments Co., Novato, CA) 
was used to apply alternating excitation with 340- and 380-nm UV light. Fluorescent 
emission at 510 nm was captured using a Sensicam digital CCD camera (Cooke Corp., 
Auburn Hills, MI) and recorded with Slidebook Version 3.0 software (Intelligent Imaging 
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Innovations, Denver, CO) on a Pentium IV computer. Changes in [Ca2+]i were calculated 
using the Slidebook 3 software (Intelligent Imaging Innovations, Denver, CO) from the 
intensity of the emitted fluorescence following excitation with 340- and 380-nm light, 
respectively, using the equation,  
 
 (Eq. 1)
 
where R represents the fluorescence intensity ratio (F340/F380) as determined during 
experiments, Q is the ratio of Fmin to Fmax at 380 nm, and Kd is the Ca2+ dissociation 
constant for fura-2. Calibration of the system was performed using a fura-2 calcium 
imaging calibration kit (Molecular Probes, Inc., Eugene, OR) and values were determined 
to be as follows: Fmin/Fmax = 23.04; Rmin = 0.31; Rmax = 8.87.  
 
Ca2+ Inhibitors. 
 The intracellular Ca2+ inhibitor thapsigargin was used in some assays when 
indicated.  Cells were incubated for 30 minutes with 10 µM thapsigargin followed by 30 
minute incubation with Fura2/AM.  In some experiments, Ca2+ imaging was performed in 
the absence of extracellular Ca2+ by using PSS without Ca2+.  BAPTA/AM, a Ca2+ 
chelator, was used during some experiments to inhibit Ca2+ signaling.  The cells were 
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pre-incubated with various concentrations of BAPTA/AM or DMSO for 10 minutes at 
37°C and then washed to remove excess BAPTA/AM or DMSO.   
 
Statistics.   
Significance was determined by a Student’s t test with two-tailed distribution.  P 
values less than 0.05 were considered significant.  Statistical significance of Ca2+ imaging 
data was determined by two-way ANOVA.  All experiments were performed in triplicate.  
Data are presented as a mean ± one SD. 
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Results 
 
 
Induction of MCP-1 Gene Expression and Protein Production.   
During B. henselae infection, monocytes and macrophages infiltrate the 
angiogenic lesions (49, 50, 64).   MCP-1 is a C-C chemokine which recruits monocytes 
and macrophages to sites of infection through binding to its CCR2B receptor (16).  We 
investigated the effect of B. henselae infection on MCP-1 expression and production in 
HMEC-1.  MCP-1 transcript levels were assayed by semi-quantitative RT-PCR at 6 and 
24 hours after infection (Fig. 4).  B. henselae-infected HMEC-1 had 1.6 times higher 
levels of MCP-1 transcript than uninfected controls at 6 hours after infection (T6) and 1.8 
times higher levels of MCP-1 transcript 24 hours after infection (T24) (Fig. 4A, B).  By 
48 hours after infection, the MCP-1 message levels for uninfected HMEC-1 began to 
approach the MCP-1 message levels of B. henselae-infected HMEC-1 (data not shown).  
This was most likely due to the absence of growth factors in culture media; after 48 hours 
of culture with no growth factors, cells start to die and MCP-1 levels increase. 
 MCP-1 levels in supernatants of infected or uninfected HMEC-1 were analyzed at 
6, 24, and 48 hours after infection by ELISA (Fig. 4C).  There was a significant increase 
in MCP-1 levels when HMEC-1 were infected with B. henselae for 6, 24, or 48 hours 
(P<0.007).  In order to determine whether the bacterial stimulating molecule was heat 
stable, bacteria were heat-killed by boiling a 100°C for 15 minutes before addition to 
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Figure 4.  B. henselae stimulated MCP-1 induction in HMEC-1.  (A) Cells were 
stimulated with B. henselae or E. coli.  Some bacteria were preincubated with polymyxin 
B sulfate.  The levels of MCP-1 mRNA in HMEC-1 were assayed by RT-PCR at 6 and 
24 hours after infection (T6, T24).  (B) RNA levels of MCP-1 were determined by 
scanning densitometry and normalized by comparison to β-actin RNA levels (C) MCP-1 
protein production was determined by ELISA at 6, 24, and 48 hours after infection. 
(UN=uninfected cells; BH=B. henselae-infected cells; PB=polymyxin B sulfate; EC=E. 
coli infected cells; *P<0.007, B. henselae infection compared to uninfected cells; 
**P<0.007, untreated E. coli compared to E. coli treated with polymyxin B sulfate).  
Results shown are one representative of three similar experiments. 
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 HMEC-1.  When bacteria were heat-killed, MCP-1 levels were not significantly lowered 
(data not shown).  These data indicate that a heat-stable molecule is responsible for MCP-
1 production. 
 
Induction of MCP-1 Gene Expression and Protein Production is Independent 
of B. henselae LPS and Endothelial Cell TLR4.   
The cell walls of Gram-negative bacteria contain LPS, which instigates a pro-
inflammatory response from cells through signaling through TLR4.  This signaling may 
lead to upregulation of pro-inflammatory cytokines such as IL-1β, TNF-α, and MCP-1.  
We investigated the role of B. henselae LPS in MCP-1 production from HMEC-1.  
Bacteria (B. henselae or E. coli) were treated with polymyxin B sulfate before addition to 
HMEC-1.  Although incubation of E. coli with polymyxin B sulfate significantly lowered 
MCP-1 gene expression and protein production from HMEC-1 at T6, T24, and T48 
(P≤0.006), polymyxin B had little effect on B. henselae-induced MCP-1 expression and 
production (Fig. 4A, B, C).  
MCP-1 production can be mediated by TLR4 or TLR2 activation (89).  Since 
HMEC-1 express TLR2 very weakly (25), we investigated whether B. henselae-induced 
MCP-1 production is mediated through TLR4 on HMEC-1.  We preincubated HMEC-1 
with a TLR4 mouse monoclonal antibody (HTA125) or an isotype control (mouse IgG2a, 
κ), then infected with B. henselae or added E. coli LPS (100 ng/ml).  Supernatants were 
collected 8 hours after infection and assayed for MCP-1 by ELISA.  While HTA125 
reduced MCP-1 production caused by E. coli LPS (P<0.002), B. henselae-induced MCP-
1 production remained unchanged by the blocking antibody (P>0.900) (Fig. 5A).  These  
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Figure 5.  MCP-1 production during inhibition assays.  Supernatants were 
collected 8 hours after infection and analyzed by ELISA for MCP-1 levels. (A) Cells 
were incubated with anti-tlr4 (HTA125) or a control isotype (mouse IgG2a, κ) for 1 
hour before infection with B. henselae or addition of E. coli LPS (100 ng/ml).  (B) 
HMEC-1 were cultured in the presence of the NFκB inhibitors PDTC or TPCK before 
infection with B. henselae or addition of E. coli LPS (1 µg/ml). (UN=uninfected 
HMEC-1; BH=B. henselae-infected HMEC-1; EC=HMEC-1 stimulated with E. coli 
LPS; *P<0.002; **P<2.00 X 10-4).  A representative of three experiments is shown. 
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data indicate that the MCP-1 produced in response to B. henselae from HUVEC does not 
involve endothelial cell TLR4 or B. henselae  LPS.   
 
MCP-1 Production Requires NFκB Activation.  
The mcp1 gene has binding sites for the transcription factors NFκB and AP-1 
(73). It was established that B. henselae can induce NFκB activation in endothelial cells 
(32).  In order to determine if the transcription factor NFκB was responsible for MCP-1 
production in HMEC-1 infected with B. henselae, NFκB inhibitors PDTC and TPCK 
were added to cells before infection.  MCP-1 production in response to  
both B. henselae infection and E. coli LPS (1µg/ml) decreased significantly in the 
presence of either inhibitor (P<0.0002) (Fig. 5B).  Induction of MCP-1 production by B. 
henselae is NFκB dependent. 
 
Low Molecular Weight Outer Membrane Proteins (OMP-1) from B. henselae 
Induce MCP-1 Production in HMEC-1.   
Since MCP-1 production in response to B. henselae infection occurs in an LPS-
independent manner, we investigated whether OMPs of the bacteria stimulate MCP-1 
production in HMEC-1.  It has been shown that OMPs induce NFκB activation in human 
umbilical cord vein endothelial cells (HUVEC) (32).  Because NFκB is one of the 
transcription factors that induces MCP-1 gene expression (73, 91), we investigated 
whether OMPs could induce production of MCP-1 from HMEC-1.  Outer membrane 
proteins were enriched from B. henselae as previously described (14).  The OMPs were 
separated into four molecular weight fractions (see Materials and Methods), and OMPs 
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were added to HMEC-1 culture at 250 ng/ml.  Out of four fractions, only the lowest 
molecular weight fraction (from 3-33 kDa), Fraction 1 (OMP-1), significantly increased 
MCP-1 production in HMEC-1 at 6 and 24 hours after addition of OMPs (P<0.002) (Fig. 
6A). OMP-1 also caused MCP-1 production from HMEC-1 in a dose-dependent manner 
(Fig. 6A).  Preincubation of OMP-1 with Polymyxin B sulfate did not abrogate its effect 
(P>0.700) (Fig. 6B), suggesting that endotoxin contamination in the OMP-1 preparation 
is not responsible for MCP-1 induction.  However, proteinase K treatment significantly 
lowered the effect of OMP-1 (P<0.0002), revealing that the factor in OMP-1 which 
upregulates MCP-1 production is probably a protein or proteins. 
 
Supernatants from B. henselae-Infected HMEC-1 Induce Chemotaxis of THP-1 
Monocytes.   
Since MCP-1 levels are heightened in response to B. henselae infection, we 
investigated whether supernatants from B. henselae-infected HMEC-1 could cause 
chemotactic migration of THP-1 monocytes.  A modified Boyden chamber assay was 
used to assess the chemotactic response of THP-1 monocytes to chemoattractants present 
in the supernatant from B. henselae-infected HMEC-1.  Migrated cells were fixed, 
stained, and counted in 5 high-powered fields.  Supernatants from uninfected HMEC-1 
were used as negative controls and supernatants from E. coli-infected HMEC-1 were 
used as positive controls.  Supernatants from B. henselae-infected HMEC-1 induced 
THP-1 chemotaxis at a level about 6 times that of supernatants from uninfected HMEC-1 
(Fig. 7) and at similar levels to supernatants from E. coli-infected HMEC-1 (4 times that 
of uninfected supernatants).  These results indicate that the levels of MCP-1 and/or other  
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Figure 6.  MCP-1 production in response to OMP fraction 1.  HMEC-1 were stimulated 
with OMP-1 under various dosages and conditions.  Supernatants were collected at 6 and 24 
(T6, T24) hours after addition of OMP-1.  MCP-1 levels were determined by ELISA.  (A) 
Dose-dependent response of HMEC-1 to various OMP-1 concentrations (B)  Effects of 
polymyxin B sulfate (30 µg/ml) (PB) and proteinase K (10 µg/ml) (PK) on OMP-1 induced 
MCP-1 production in HMEC-1. (*P<0.002; **P<2.00 X 10-4).  A representative of three 
experiments is shown. 
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Figure 7.  THP-1 monocyte chemotaxis in response to supernatants from B. 
henselae-infected HMEC.  (A)  Chemotaxis of THP-1 monocytes in response to 
uninfected HMEC supernatants, B. henselae-infected HMEC supernatants (BH), or E. 
coli-infected HMEC supernatants (EC).  Results are expressed as a chemotactic index.  
The number of migrated THP-1 in five microscopic fields was averaged for supernatants 
from uninfected, B. henselae-infected, and E. coli-infected HMEC-1.  The chemotactic 
index for cells which migrated in response to uninfected supernatants was set at one, and 
other samples were normalized accordingly.   Results shown are the mean of three 
separate experiments.   
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chemokines in supernatants from infected HMEC-1 are sufficient to cause chemotaxis of 
monocytes.   
 
CXCL8 Production from a Variety of Cell Types Infected with B. henselae. 
CXCL8 plays a role in angiogenesis through induction of MMP production, 
endothelial cell survival, and capillary tubule formation (52).  It has been reported that 
CXCL8 production is enhanced from endothelial cells and epithelial cells by an NFκB-
dependent pathway in the presence of B. henselae (32, 77).  We tested a variety of cell 
types for production of CXCL8 in response to B. henselae at an MOI of 100.  Two types 
of endothelial cells, HMEC-1 and HUVEC (see Materials and Methods), upregulated 
CXCL8 in response to B. henselae 24 hours after infection (Fig. 8A).  Other cells which 
may be important for B. henselae pathogenesis (hepatocytes and monocyte-derived 
macrophages) were also examined for their ability to upregulate CXCL8 in response to B. 
henselae.  They also markedly upregulated CXCL8 during infection (Fig. 8B, C).   We 
have previously reported (71) that B. henselae-infected THP-1 do not enhance CXCL8 
production at an MOI=500, which conflicts with the results presented here.  However, 
this study used Vitamin D3 for monocyte differentiation (see Materials and Methods) in 
place of phorbol myristate acetate (PMA), which lowers background CXCL8 production; 
thus the differences between uninfected and infected macrophages were more clearly 
distinguishable.   
Furthermore, we examined HUVEC for CXCL8 receptors CXCR1 and CXCR2 
expression in the presence of B. henselae.  While CXCR1 RNA levels were not 
significantly different between uninfected and infected HUVEC (data not shown),  
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Figure 8. B. henselae-induced CXCL8 production assayed by ELISA.  (A) B. 
henselae induced CXCL8 production from human umbilical vein endothelial cells 
(HUVEC) and; human microvascular endothelial cells (HMEC-1).  (B) B. henselae-
induced CXCL8 production from hepatocytes (HepG2).  (C) B. henselae-induced 
CXCL8 production from monocyte-derived macrophages (THP-1). (Un=Uninfected 
cells;  Bh=B. henselae-infected cells; *P<0.001). 
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CXCR2 levels were around four times higher in B. henselae-infected cells than in 
uninfected cells (Fig. 9A, B).  B. henselae causes CXCL8 production from macrophages, 
endothelial cells, and hepatocytes; B. henselae also induces CXCL2 expression in 
endothelial cells, indicating a putative autocrine mechanism during B. henselae infection 
of endothelial cells. 
 
Effect of Blocking CXCL8 on B. henselae-Induced Endothelial Cell Proliferation. 
B. henselae causes more endothelial cell proliferation at MOIs of under 50 than at 
higher MOIs (77).  This is most likely due to a cytotoxic effect from a factor coded by the 
virB operon at higher MOIs.  However, other aspects of B. henselae-induced 
angiogenesis such  as inhibition of apoptosis, capillary tube formation, and NFκB-
dependent proinflammatory activation correlate positively with bacterial numbers(42, 43, 
72).  Since it has been reported that CXCL8 directly mediates endothelial cell survival 
and proliferation (46),  we examined the role of CXCL8 in B. henselae-induced HUVEC 
proliferation (Fig. 10A).  Cells were incubated with B. henselae (MOI of 50) or rCXCL8 
(100 ng/ml).  Cells were also treated with anti-human CXCL8 or a control IgG1 (10 
µg/ml).  After 3 days, pictures were taken of the wells (Fig. 9A) and cells were counted 
(Fig. 10B).  Both B. henselae and rCXCL8 induced proliferation as compared to 
unstimulated cells. The presence of a CXCL8 antibody quenched the proliferative effect 
of B. henselae and rCXCL8, while an isotype control did not.  These data point to a 
putative role for CXCL8 during B. henselae-induced proliferation. 
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Figure 9.  CXCR2 expression in HUVEC.  (A) RNA was extracted from uninfected 
and B. henselae-infected HUVEC and subjected to semi-quantitative RT-PCR.  (B) 
Scanning densitometry determined the relative intensities of CXCR2 expression when 
normalized to β-actin house-keeping gene expression.  Relative CXCR2 induction was 
measured as a ratio of CXCR2 to β-actin when this ratio in uninfected cells was 
normalized to 1.  (UN=uninfected HUVEC; BH= B. henselae-infected HUVEC). 
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Figure 10. Effect of CXCL8 on HUVEC proliferation in response to B. 
henselae.  HUVEC were uninfected (UN) or infected with B. henselae (BH) or 
incubated with rCXCL8 in either the presence or absence of a neutralizing anti-
CXCL8 antibody or an isotype control (mouse IgG1) for 3 days.  (A) Digital 
pictures of typical phase-contrast microscopic fields. (B) Cell proliferation 
expressed as a graph of average cell number per high-powered field.  *P<0.008. 
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Role of CXCL8 in B. henselae-Induced Endothelial Cell Survival. 
The balance between Bax (apoptotic) and Bcl-2 (anti-apoptotic) is important for 
endothelial cell survival or apoptosis.  We examined HUVEC infected with B. henselae 
at an MOI of 100 for expression of Bcl-2 family members Bcl-2 and Bax.  CXCL8 
induces increased Bcl-2 expression and decreased Bax expression (53).  While it has been 
reported that B. henselae inhibits apoptosis of HUVEC though inhibition of caspases 
(43), the Bcl-2 and Bax levels in uninfected and B. henselae-infected HUVEC have not 
been previously compared.  We examined Bax and Bcl-2 levels in HUVEC by real-time 
PCR.  We found that B. henselae-infected HUVEC had almost undetectable levels of Bax 
expression and about four times enhanced Bcl-2 expression (Fig. 11A) when compared 
with uninfected controls and normalized to a β-actin housekeeping gene.  This increased 
Bcl-2/Bax ratio probably biases the cell into an anti-apoptotic state.  We examined the 
role of CXCL8 on B. henselae-enhanced HUVEC survival.  When anti-CXCL8 was 
added to HUVEC in the presence of B. henselae, the anti-apoptotic response of the cells 
decreased markedly (Fig. 11B, C).  Bax levels were raised about fivefold in the presence 
of anti-CXCL8 but not in the presence of control IgG1 (Fig. 11B).  Conversely, Bcl-2 
levels induced by B. henselae infection dropped six fold in the presence of a CXCL8 
neutralizing antibody (Fig. 11C).  These results reveal a possible autocrine role for 
CXCL8 in B. henselae-stimulated endothelial cell survival. 
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Figure 11.  Effect of anti-CXCL8 on inhibition of HUVEC apoptosis induced by 
B. henselae.  (A) B. henselae causes enhanced Bcl-2 expression and decreased Bax 
expression in HUVEC. Results are expressed as relative expression units, a ratio of 
amounts of Bcl-2 or Bax transcripts to β-actin transcript amounts.  (B) Bax expression 
reduced by B. henselae is increased in the presence of a neutralzing antibody to 
CXCL8.  (C) Bcl-2 expression increased by B. henselae is decreased in the presence 
of anti-CXCL8. (UN=uninfected HUVEC; BH=B. henselae–infected HUVEC; 
rCXCL=rCXCL8-treated HUVEC; *P<0.01). 
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Role of CXCL8 in B. henselae-Induced Capillary Tube Formation.  
In vitro angiogenesis assays have revealed a pro-angiogenic response of HUVEC 
to B. henselae infection (42).  HUVEC infected with B. henselae seeded on a GFR 
matrigel exhibited advanced capillary tube formation when compared to uninfected 
HUVEC (Fig. 12).  HUVEC incubated with rCXCL8 also showed enhanced capillary 
tube formation.  When anti-CXCL8 was present in the matrigel, the capillary tube 
formation was visibly diminished (Fig. 12).  The presence of an isotype control, however, 
had no such effect on tube formation. These data delineate further an autocrine role for 
CXCL8 during B. henselae infection. 
 
B. henselae Secreted Proteins (BHSP) Contain GROEL and BadA.   
B. henselae secreted proteins have been implicated in endothelial cell 
proliferation (59).  However, the TFSS encoded by the virB operon is not responsible for 
endothelial cell proliferation, and is turned on only inside the endothelial cell (77, 79).  
Thus in order to avoid this cytotoxic effect and study simply the effect of TFSS-
independent secreted proteins, we isolated secreted proteins (SP) from B. henselae 
conditioned media as described in Materials and Methods.  The proteins were analyzed 
by electrophoresis and tested for the presence of GROEL, a heat shock protein that is 
potentially secreted, and BadA, an immunogenic adhesion (Fig. 13A, B), by western blot 
and dot blot, respectively.  Both proteins were present in the SP fractions.  The presence 
of GROEL was expected, as it has been previously found in conditioned media from B.  
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Figure 12.  Effect of anti-CXCL8 on B. henselae-induced capillary formation 
in a GFR matrigel.  HUVEC were infected with B. henselae (BH) or uninfected 
(UN) and seeded on a GFR matrigel containing no antibody, a control antibody 
(mouse IgG1, 10 µg/ml), or anti-CXCL8 (10 µg/ml).  Uninfected HUVEC were 
then either stimulated with CXCL8 (100 ng/ml) or left alone.  Pictures were taken 
after 24 hours.  
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Figure 13.  B. henselae secreted proteins (BHSP) contain BadA and GROEL.  
BHSP were analyzed by western blot for GROEL (A) and dot blot for BadA (B).  A 
medium control (MC) served to rule out non-specific antibody binding to proteins in 
the medium.  Secreted proteins from a BadA mutant (∆BadA) were also used as a 
negative control for the BadA dot blot. 
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henselae (63).  However, the presence of BadA was unexpected since it is an adhesin; 
perhaps it is shed from the bacteria during liquid culture.  Thus we identified two 
potentially important proteins in the B. henselae secreted protein (BHSP) fraction. 
 
BHSP Induce a Proliferative Response in HUVEC.   
There has been controversy in the literature concerning whether bacteria-host cell 
contact is needed for endothelial cell proliferation to occur (20, 59).  Therefore we tested 
the ability of BHSP to cause proliferation in HUVEC.  At a concentration of 250 µg/ml, 
the BHSP caused HUVEC proliferation, while a medium control (MC) at the same 
concentration did not (Fig. 14A, B).  The proliferative response was almost 3 times that 
of untreated controls.  In addition, the morphology of the cells incubated with BHSP was 
similar to the morphology of HUVEC when they are infected with B. henselae at MOIs 
of 50 or lower.  They are elongated and display morphology consistent with proliferating 
cells in the presence of VEGF (77). 
 
BHSP Induce an Intracellular Ca2+ Response in HUVEC.   
Ca2+ signals play a key role in angiogenesis and other cellular processes (2).  We 
tested the ability of BHSP to induce a Ca2+ rise in HUVEC.  Interestingly, when 250 µg 
BHSP were added to HUVEC, intracellular Ca2+ concentrations rose rapidly to 100 nM 
(Fig. 15A).  When a medium control was added to HUVEC, there was no Ca2+ rise (Fig. 
15A).  The peak Ca2+ concentrations were significantly different (P<0.05) from base 
levels (Fig. 15B).   
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Figure 14.  BHSP cause HUVEC proliferation.  HUVEC were incubated with a 
medium control (MC) or BHSP (250 µg/ml) and incubated 96 hours.  Cells were 
viewed by inverted microscope and pictures were taken to view qualitative cell 
numbers (A).  Five fields per well were counted and the average number for media 
controls was normalized to 1 (B). 
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 Figure 15.  BHSP cause a Ca2+ rise in HUVEC.  BHSP were added to HUVEC 
mounted on a coverslip and intracellular Ca2+ was quantified as described in Materials 
and Methods.  (A) One HUVEC Ca2+ response to BHSP (250 µg/ml) and a medium 
control (MC).  (B)  The average peak and baseline Ca2+ levels were compared for all 
cells. (*P<0.05; results are expressed as the mean plus one standard deviation). 
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BHSP Induce an Intracellular Ca2+ Response in HUVEC from Intracellular Stores. 
In order to determine if the intracellular Ca2+ response from HUVEC resulted 
from extracellular Ca2+ entering the cell or from Ca2+ mobilization from intracellular 
stores, we tested the Ca2+ response to BHSP under various conditions.  Under 
extracellular Ca2+-free conditions (0 Ca2+), the Ca2+ response did not change significantly 
(Fig. 16A, B) upon application of BHSP.  Thus the Ca2+ response derived from inside the 
cell.  Next we preincubated HUVEC with 1 µM thapsigargin (THAPS), a Ca2+ ATPase 
inhibitor which depletes intracellular Ca2+ stores (10, 83).  In the presence of the 
inhibitor, the Ca2+  levels did not increase in response to BHSP (Fig. 15A) and the peak 
values of Ca2+ concentration were significantly lowered (Fig. 16B, P<0.05).  Therefore 
the BHSP-derived Ca2+ response in HUVEC derives from intracellular Ca2+ pools, which 
have been implicated as the crucial Ca2+ pool for angiogenesis (10, 80, 83).    
 
BHSP-Induced HUVEC Proliferation Requires Ca2+. 
 Given that intracellular Ca2+ is important for angiogenesis and that BHSP induce 
such a high concentration of intracellular Ca2+ as well as HUVEC proliferation, we 
investigated whether HUVEC proliferation induced by BHSP would still occur in the 
presence of a Ca2+ chelator, BAPTA/AM.  After 10 minute pre-incubation with 
BAPTA/AM at concentrations of 1 µM BAPTA/AM or equivalent volumes of a DMSO 
vehicle control, the cells were washed and BHSP or medium controls were added.  In the 
presence of BAPTA/AM, the HUVEC proliferation was reduced almost 50% (Fig. 17).  
We also determined that whole B. henselae-induced proliferation is also lowered when  
 55
 
 
Figure 16.  BHSP cause a Ca2+ rise in HUVEC from intracellular stores.  
HUVEC were either incubated with 1 µM thapsigargin(THAP) for 30 minutes 
followed by incubation with FURA-2-AM (20 µM), or incubated with FURA-2-
AM and assayed in Ca2+-free conditions.  BHSP were added to HUVEC and 
intracellular Ca2+ was quantified as described in Materials and Methods.  (A) 
Responses to BHSP from cells assayed with Ca2+ present (control), cells assayed 
in the absence of Ca2+ (0 Ca), and cells incubated with 1 µM thapsigargin 
(THAPS).  (B) The average peak and baseline Ca2+ levels were compared for all 
cells.  Results are expressed as the mean plus one standard deviation.  (*P<0.05). 
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Figure 17.  Ca2+ signaling is important for BHSP-mediated HUVEC 
proliferation.  HUVEC were preincubated with 1 µM BAPTA/AM or a DMSO 
vehicle control.  A medium control (MC) or BHSP were added to HUVEC at 
indicated concentrations 250 µg/ml, or cells were infected at an MOI of 50 with B. 
henselae (BH).  After 72 hours, cells were photographed and five high-powered 
fields (HPF) were counted and averaged (*P<0.02; **P<0.04).  
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HUVEC are pre-incubated with BAPTA/AM.  Consequently, intracellular Ca2+ is 
important for BHSP- and live B. henselae-induced HUVEC proliferation. 
 
BHSP Induce CXCL8 Production from HUVEC. 
We have determined that CXCL8 plays an autocrine role in B. henselae –induced 
endothelial cell survival, proliferation, and capillary tube formation.  In order to 
determine if the BHSP were inducing proliferation through CXCL8 production, we tested 
the ability of BHSP to induce CXCL8 production from HUVEC.  When BHSP were 
added to HUVEC, the CXCL8 levels increased (Fig. 18A).  CXCL8 production did not 
increase in the presence of a medium control.  Additionally, when BAPTA/AM was 
added to HUVEC before addition of BHSP, the CXCL8 levels dropped significantly (Fig. 
18B).  These data indicate a role for intracellular Ca2+ activity in CXCL8 production 
mediated by BHSP.  
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Figure 18.  BHSP induce CXCL8 production from HUVEC.  (A) HUVEC were 
incubated with a medium control (MC) or BHSP at indicated concentrations (µg/ml) 
for 24 hours.  Supernatants were collected and ELISA was performed.  (B) HUVEC 
were preincubated with BAPTA/AM or DMSO control.  BHSP or media controls 
were added at shown concentrations (µg/ml) and supernatants were collected after 
24 hours and ELISA was performed. *P<0.03. 
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Discussion 
 
B. henselae, the etiologic agent of CSD, is a fastidious, gram-negative, oxidase-
negative, aerobic bacillus (11, 13).  B. henselae infections cause a range of symptoms 
from lymphadenopathy (CSD) to systemic disease.  The severity of the disease tends to 
relate to immune status.  Immunocompromised patients such as AIDS patients, chronic 
alcoholics, or immunosuppressed people can develop systemic disease.  However, 
immunocompetent patients may still present with systemic bacteremia, endocarditis, and 
bacillary angiomatosis. 
B. henselae can cause vascular proliferative lesions (5) into which macrophages 
infiltrate during infection (49, 50, 64).  In the paracrine and autocrine model of B. 
henselae-induced angiogenesis (Fig. 2), macrophages are implicated as effector cells; 
upon stimulation by B. henselae, they secrete VEGF and other endothelial cell mitogens 
(71).  Concurrently, endothelial cells upregulate pro-angiogenic factors such as 
chemokines, inhibit apoptosis through inhibition of caspases (44), and upregulate 
adhesion molecules (32) which may promote proliferation.  In this study we investigated 
the endothelial cell mediators of angiogenesis which are induced upon infection with B. 
henselae.  Specifically, we determined that B. henselae (i) upregulates MCP-1 
production, which brings the effector cell macrophage into the site of infection, where it 
secretes VEGF and CXCL8 which would promote angiogenesis; (ii) induces CXCL8 
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production and CXCL8 receptor CXCR2 expression, which promotes angiogenesis in an 
autocrine manner by enhancing endothelial cell survival, endothelial cell proliferation, 
and capillary tube formation; and (iii) causes an intracellular Ca2+ rise from intracellular 
pools which leads to NFκB-directed pro-inflammatory activation and endothelial cell 
proliferation.  These mediators of angiogenesis which are induced by the bacterium 
probably play a pivotal role in B. henselae-induced angiogenesis.  When the additional 
factors from peripheral cells are considered, a model of B. henselae-induced angiogenesis 
emerges (Fig. 19).  
Macrophages and monocytes infiltrate lesions caused by BA (49, 50, 64).  
Macrophages secrete VEGF upon B. henselae infection, which probably contributes to 
angiogenesis during infection (41, 71).  We investigated the mechanism by which the 
macrophage is brought into the site of infection by examining the expression and 
production of the chemokine MCP-1 from B. henselae-infected HMEC-1.  MCP-1 is a 
member of the C-C chemokine family and is produced and secreted by monocytes, 
fibroblasts, and vascular endothelial cells.  MCP-1 then interacts with its CCR2B receptor 
on monocytes and macrophages to cause chemotaxis (16).  MCP-1 can also directly 
promote angiogenesis.  When tumor cells are transfected with mcp-1 gene and injected 
into a murine model, angiogenesis is stimulated (68).  In addition, MCP-1 implants 
induce angiogenesis in a rabbit cornea (88).  During B. henselae infection, MCP-1 
released from endothelial cells, most likely in addition to other factors, causes chemotaxis 
of monocytes and macrophages to the site of infection, thereby promoting an angiogenic 
state by recruiting the effector cell.
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Figure 19.  Endothelial cell mediators of angiogenesis during B. henselae  
infection.  This model depicts the mediators of angiogenesis that are induced 
by B. henselae  from endothelial cells (EC). When ECs are infected with B. 
henselae  (BH), MCP-1 is produced and recruits macrophages (Mφ), which 
secrete VEGF when they are infected.   CXCL8 is also produced from ECs, 
leading to enhanced EC survival and capillary tube formation.  BH secretes 
proteins (BHSP), which induce a Ca2+ spike from intracellular stores and 
contribute to NFκB-dependent CXCL8 production and EC proliferation.  
These mechanisms culminate in B. henselae-induced angiogenesis. 
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             Bacterial pathogens such as E. coli, Orientia tsutsugamushi, and Porphorymonas 
gingivalis increase chemokine production and secretion (18, 45, 99).  MCP-1 is induced 
in HMEC-1 in response to B. henselae infection (Fig. 4).  Both mRNA and protein levels 
are upregulated; mRNA levels are higher than uninfected controls in B. henselae-infected 
HMEC-1 at 6 and 24 hours after infection, while protein levels in infected cells are higher 
at 6, 24, and 48 hours after infection.  Furthermore, supernatants from B. henselae-
infected HMEC-1 caused chemotaxis of THP-1 monocytes (Fig. 7).  Thus the levels of 
MCP-1 produced by HMEC-1 in response to B. henselae infection in vitro are sufficient 
to function as a chemoattractant for monocytes.  Results also reveal that the bacterial 
factor which causes MCP-1 production is probably a heat stable molecule. 
The LPS of B. henselae has recently been characterized as containing a lipid A 
possessing features known to reduce endotoxicity, including a pentaacyl lipid A and a 
long-chain fatty acid (97).  B. henselae LPS induces TLR4 1000-fold lower than 
Salmonella enterica sv. Friedenau LPS (97).  In addition, LPS from B. quintana, which is 
likely quite similar to B. henselae LPS, induces GRO-CINC-1 in rats but not TNF in rats 
or human whole blood (62).  B. henselae LPS also does not induce TNF in cats. In this 
study, the addition of polymyxin B sulfate to B. henselae before infection of HMEC-1 did 
not reduce MCP-1 production; however, polymyxin B sulfate had a significant lowering 
effect on E. coli-induced MCP-1 production (Fig. 4).  These data corroborate with the 
low endotoxicity of LPS from Bartonella spp. to imply a limited or nonexistent role for 
LPS in B. henselae-induced MCP-1 production. 
 Toll-like receptors activated by various microbial products can cause expression 
and production of chemokines (23, 24, 57), including MCP-1 (76).  LPS, a TLR4 agonist, 
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causes MCP-1 production in a TLR4-dependent manner (89).  Most studies confirm that 
MCP-1 production is TLR4-mediated, and usually caused by LPS in a bacterial infection.  
However, recently it was discovered that TLR4-deficient and TLR4-competent mice have 
the same MCP-1 response to infection by Leishmania major (6), which is known to cause 
chemokine production early in infection (40).  Our findings indicate that MCP-1 
production in response to B. henselae infection is not TLR4-dependent (Fig. 5A).  In 
contrast, E. coli LPS-induced MCP-1 production was lowered in the presence of a TLR4 
monoclonal antibody.  These data suggest the possibility of an alternate pathway to TLR4 
activation for the MCP-1 production from B. henselae-infected HMEC-1.  Furthermore, 
these results again exclude B. henselae LPS from a role in MCP-1 production.  HMEC-1 
express TLR1, TLR3, TLR4, and TLR5 but express TLR2 very weakly, which is why 
they are unresponsive to TLR2 ligands (25).  Thus the MCP-1 production investigated in 
this study is probably not TLR4- or TLR2-mediated.  Other TLR or similar receptor 
pathways must be investigated to pinpoint the exact mechanism of MCP-1 induction in 
HMEC-1 in response to B. henselae.   
The mcp-1 gene contains binding sites for both NFκB and AP-1 (73, 91), and both 
transcription factors have been implicated in mcp-1 expression (18, 94).   It has been 
established that B. henselae induces NFκB-dependent upregulation of adhesion molecules 
in HUVEC independent of LPS (32).  The findings from our study suggest the 
independence of MCP-1 expression and protein production from B. henselae LPS.  In 
addition, we used two NFκB inhibitors to determine whether MCP-1 protein production 
requires NFκB activation.  Diverse NFκB inhibitors have been used with HMEC-1 
previously in similar experiments (18).  PDTC is an antioxidant that inhibits the 
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phosphorylation of IκB (66, 78) and TPCK inhibits proteosome-dependent degradation of 
inhibitory peptides (58).  Consequently, through the use of these inhibitors, we 
demonstrated that MCP-1 production caused by B. henselae in HMEC-1 is NFκB-
dependent (Fig. 5B). 
OMPs of B. henselae are important for pathogenesis (14, 32).  Data presented 
here reveal the ability of B. henselae Houston-1 OMPs, specifically OMPs of low 
molecular weight, to enhance production of the C-C chemokine MCP-1 from HMEC-1 
(Fig. 6A).  This upregulation is again independent of LPS, as shown by incubation of 
OMP-1 with polymyxin B sulfate before addition to HMEC-1 (Fig. 6B).   These data 
point to a heat-stable low molecular weight OMP of B. henselae Houston-1 that 
contributes at least in part to B. henselae-induced MCP-1 production from endothelial 
cells.  Further studies are needed in order to specify the putative OMP that causes MCP-1 
upregulation in endothelial cells. 
We have described upregulation of gene expression and protein production of the 
chemokine MCP-1 in response to B. henselae infection.  This stimulation of HMEC-1 is 
independent of B. henselae LPS and toll-like receptor 4 but dependent on NFκB activity.  
MCP-1 produced by infected HMEC-1 most likely contributes to the ability of 
conditioned media from these cells to induce monocyte chemotaxis.  The recruitment of 
macrophages by MCP-1 produced from infected endothelial cells could have broad 
implications on mechanisms of angiogenesis during this infection.  Specifically, the 
macrophage effector cell which secretes VEGF and other angiogenic factors is brought to 
the site of infection.  Pathogenic angiogenesis provides actively growing target cells for 
B. henselae in an enriched vascularized microenvironment, and while the specific role of 
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MCP-1 induction in this phenomenon is not completely understood, we suggest that 
recruitment of the monocyte/macrophage effector cell is an important component of the 
pathway. 
Angiogenesis is a complex process involving several key steps.  These steps 
include (i) inhibition of endothelial cell apoptosis, (ii) endothelial cell proliferation, (iii) 
breakdown of the extracellular matrix by MMPs, and (iv) capillary tube formation.  
CXCL8 can promote each of these steps.  Since B. henselae upregulates CXCL8 
production from endothelial cells (21, 71), we investigated a putative autocrine role for 
CXCL8 in B. henselae-induced angiogenesis.   
There are conflicting reports on whether endothelial cells actively proliferate or 
whether they simply exhibit enhanced survival in the presence of B. henselae (43, 77).  
Endothelial cell proliferation in BA most likely comes from a combination of inhibition 
of apoptosis and mitogenic stimulation.  In addition, endothelial cell proliferation and 
angiogenesis probably result from the effects of the bacterium on both the endothelial 
cells and peripheral cells such as epithelial cells and macrophages (41, 71).  While this 
particular study focuses on the autocrine role of CXCL8, a paracrine role should not be 
overlooked as many cell types produce CXCL8 after infection with B. henselae (Fig. 8).  
Furthermore, the bacterium causes an upregulation of expression of one of the CXCL8 
receptors, CXCR2 (Fig. 9).  This may represent a mechanism by which the effects of 
CXCL8 on the endothelial cell are enhanced because the receptor is present at elevated 
levels.  When the fact that CXCL8 production is upregulated from endothelial and other 
cells is combined with the information that CXCR2 expression is also enhanced during 
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endothelial cell infection, a model emerges whereby CXCL8 signaling is extremely 
elevated in the endothelial cell during B. henselae infection. 
The balance between Bax and Bcl-2 is important for endothelial cell survival or 
apoptosis.  CXCL8 induces an increase in Bcl-2 expression and a decrease in Bax 
expression, most likely favoring survival over apoptosis in endothelial cells (52).  It has 
been shown that B. quintana can modulate the cell-programmed death of HUVEC-C by 
increasing Bcl-2 expression (54).  In this study, we examined expression of two Bcl-2 
family members, Bcl-2 (anti-apoptotic) and Bax (apoptotic) in HUVEC by real time RT-
PCR.  In the presence of B. henselae, Bax is decreased and Bcl-2 is increased (Fig. 11A).  
These increases and decreases are quite dramatic alone; however, when the ratio of Bcl-2 
to Bax is considered, the comparison is even more drastic.  This is the first report of B. 
henselae mediating Bax and Bcl-2 expression in endothelial cells.  In addition, the data 
reveal a possible role for CXCL8 in this prevention of apoptosis since the presence of 
anti-CXCL8 abrogates the higher Bcl2 levels and the lower Bax levels induced by B. 
henselae (Fig. 11B, C).   
 These data also implicate CXCL8 as a mediator of endothelial cell proliferation 
and capillary tube formation during infection.  Both aspects of angiogenesis were 
decreased in the presence of a CXCL8 neutralizing antibody (Figs. 10, 12).  However, 
other mechanisms are probably also involved in proliferation, including the activity of 
growth factors such as VEGF from other cells.  It has been shown that while B. henselae 
cause endothelial cells to proliferate, this proliferation is inhibited at higher MOIs as a 
result of a cytotoxic effect from the B. henselae  TFSS (77).  Our proliferation results 
agreed with this phenomenon; at MOIs above 50, endothelial cell proliferation was 
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decreased.  However, the other aspects of angiogenesis (capillary tube formation, 
enhanced endothelial cell survival, and CXCL8 production) increased at an MOI of 100 
when compared to an MOI of 50 (data not shown).  These results suggest that the 
cytotoxic effect of the products of the virB does not have an effect on expression of Bcl-2 
family members or capillary tube formation.  Thus the pro-angiogenic effect of B. 
henselae may consist of a complicated fusion of many host cell and bacterial factors.  
Nevertheless, CXCL8 seems to play an autocrine and possible paracrine role in B. 
henselae-induced angiogenesis, representing a mechanism by which the bacterium causes 
upregulation of CXCL8 thereby increasing its survival by expanding its host cell 
reservoir.  An assessment of the contribution of each of these in vitro components toward 
the overall angiogenesis mediated by B. henselae is still unfinished, and it will require 
extensive in vivo and in vitro studies.  
 B. henselae secreted proteins (BHSP), or conditioned media, have been shown to 
induce endothelial cell proliferation (59).  These proteins are isolated from B. henselae 
grown on chocolate agar and resuspended in liquid medium for 24 hours.  There is a 
cytotoxic effect from the TFSS of B. henselae, which mediates secretion of BepD into 
endothelial cells (80), at MOIs above 50.  When a virB mutant is used to infect HUVEC, 
the proliferation is 4-fold higher than with wildtype B. henselae (77).  Thus it was 
determined that the TFSS triggers a cytotoxic effect in HUVEC.  The virB promoter is 
only active inside the cell; B. henselae containing a GFP reporter construct driven by the 
virB promoter are not green outside of the cell (79).  BHSP therefore contain only low 
levels, if any, of TFSS-transported proteins.   
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NFκB activation links the upregulation of MCP-1 and CXCL8 during B. henselae 
infection.  Thus we investigated upstream of NFκB activation by examining the 
intracellular Ca2+ response to bacterial secreted proteins.  In this study we determined that 
BHSP in fact cause endothelial cell proliferation (Fig. 14) and that this proliferation is 
dependent on Ca2+ signaling, since in the presence of the Ca2+ chelator BAPTA/AM 
HUVEC proliferation was lowered (Fig. 17).  Additionally, we demonstrated that BHSP 
induce a Ca2+ elevation in HUVEC, while a medium control did not have the same effect 
(Fig. 15).  Furthermore, we showed that the origin of the Ca2+ response to BHSP is an 
intracellular store, since the intracellular Ca2+ store inhibitor thapsigargin abolished the 
BHSP-induced Ca2+ rise in HUVEC (Fig. 16).   
CXCL8 is an important mediator of angiogenesis and is important for HUVEC 
survival and capillary tube formation during B. henselae infection of HUVEC.  Since the 
BHSP induced HUVEC proliferation, we sought to ascertain whether BHSP induce 
CXCL8 production from HUVEC.  In the presence of BHSP, CXCL8 production was 
raised about four times higher than a medium control (Fig. 18A, P<0.001).  However, the 
CXCL8 levels in the presence of BHSP did not increase above 100 pg/ml (Fig. 18A, B).  
These CXCL8 levels are lower than those elicited by live B. henselae (Fig. 8).  Thus the 
question arises: Are these CXCL8 levels sufficient to cause HUVEC proliferation or is 
there another proliferative pathway activated by BHSP?  In fact, during proliferation 
assays, HUVEC are seeded at a low density (103 HUVEC/well of a 96-well plate) in 
order to allow for proliferation over 3-4 days.  Thus while MOIs of live bacteria take into 
account the cell numbers, the concentrations of BHSP are determined as µg/ml.  
Therefore during proliferation assays, higher CXCL8 levels may be elicited as a result of 
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lower numbers of cells.  Unfortunately, since the HUVEC proliferate over 3 or 4 days, 
measurement of CXCL8 levels would be skewed as there are more cells in BHSP-treated 
wells.  Additionally, the BHSP are present for 3 days and may cause more CXCL8 
production over that time course.  Consequently, we propose that while the CXCL8 
responses to BHSP were not as robust as the response to live B. henselae, these levels 
may be sufficient to cause HUVEC proliferation.  CXCL8 production enhanced by BHSP 
was lowered in the presence of a Ca2+ chelator BAPTA/AM (Fig. 18B).  NFκB activation 
can be mediated by intracellular Ca2+ signaling, and BHSP induction of CXCL8 appears 
to be Ca2+-dependent.   
The factor which induces the Ca2+ rise and subsequent effects is still unknown.  
We determined that BHSP contain BadA and GROEL (Fig.13), both which are important 
during B. henselae infection of endothelial cells (63, 72).  BadA binds to the extracellular 
matrix proteins collagen, laminin, and fibronectin (72).  This could be responsible for the 
Ca2+ rise in HUVEC.  GROEL is mitogenic for endothelial cells, which may contribute to 
HUVEC proliferation and CXCL8 production mediated by BHSP.  The TFSS mediates 
CXCL8 production in HUVEC as well (77); perhaps low levels of some of the effectors 
translocated by the TFSS are present in the BHSP or the components on the bacterial 
membrane are present in BHSP.  Further studies are necessary to determine the factor 
responsible for proliferation and CXCL8 production, including proteomic analysis of the 
BHSP and functional assays of these species present in BHSP.    
We propose that the BHSP experiments may evolve into an animal model of B. 
henselae-induced angiogenesis.  A rhesus macaque model of B. quintana infection was 
developed in which the levels of bacteria mimicked human infection (98).  No infection 
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model in mice has been successfully developed; Arvand et.al. showed bacterial presence 
up to one week after infection in C57/BL6 mice (8), after which the bacteria were 
cleared.  Perhaps the BHSP could be used in an angiogenic model such as an in vivo 
matrigel in mice or the chicken embryo assay, which may circumvent the problems 
associated with clearance of B. henselae during mice infection. 
 Endothelial cell mediators of angiogenesis induced by B. henselae contribute to 
the overall pathology in B. henselae infection.  In this study we identified three mediators 
of angiogenesis induced from the endothelial cell as a result of bacterial factors: MCP-1, 
which brings the macrophage effector cell into the site of infection; CXCL8, which 
directly promotes angiogenesis in an autocrine manner; and intracellular Ca2+ activity, 
which contributes to endothelial cell proliferation and NFκB activation.  These factors 
and others from peripheral cells culminate in the unique angiogenic lesions seen during 
B. henselae infection in the immunocompromised.  A better understanding of how B. 
henselae causes angio-proliferation could lead to the development of improved 
therapeutics and contribute to the understanding of interactions between intracellular 
bacteria and host cells. 
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